Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
O.T. - Hope you didn't buy too many KNP or at least got out in time! I didn't buy any. As for GBK, only time will tell if and when the Chinese allow it to rebound.
On another note, I think we will be pleasantly surprised soon with Alda. Just a gut feeling.
Yes, I have to say those are my favourites, nuts and chocolate melted on top! :)
Sorry drumstick; I know the term has been used before, but makapia, you are too funny! After all drumstick you have to find a little humour in a time of doldrums in a stock! :)
Yes I believe GBK will be a good money maker. Just need to get through some cheaper paper first, which should't be too far off me thinks.
I personaly like grape cool aid; but only when it is electric! :)
Yes I listened to that interview. Puts a different light/perspective on Alda for me, long term anyway. Hopefully we start to hear news with some real meat in it this coming fall and winter.
Stem Cell Therapeutics Corp. Announces Funding of the Traumatic Brain Injury (TBI) Clinical Study and Issuance of Stock Options
CALGARY, ALBERTA, Aug 30, 2010 (MARKETWIRE via COMTEX News Network) --
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) wishes to announce budgetary approval of the SCT-sponsored investigator-lead Phase IIa study entitled "A Phase IIa, Single Center, Open Label Study to Characterize the Safety of Human Chorionic Gonadotrophin (hCG) and Epoeitin Alpha (EPO) in Traumatic Brain Injury". After strategic discussions between management and the Board of Directors a decision was made to go forward with the TBI clinical study. SCT will provide the funding necessary to complete the enrollment of 10 TBI patients in a single center open label study, lead by Dr. David Zygun, to characterize the safety of hCG and EPO in traumatic brain injury. A series of efficacy endpoints are part of the trial design in order to access various aspects of neurological status.
Dr. Alan Moore, President and CEO of SCT said "We are excited to fund this study, which is a significant milestone, and demonstrates the Company's commitment to the advancement of our programs. This is an important step for SCT as we move forward and highlights our dedication to prospering in the biotechnology area. We are in the process of evaluating all our programs and plan to make announcements as decisions are made."
The Company also wishes to announce the issuance of stock options to the directors of the Company. SCT has issued an aggregate of 1,550,000 stock options to three of the Company's Board of Directors at an exercise price of C$0.10 per share. These options will expire no later than August 27, 2015 subject to applicable vesting provisions. These options were awarded in accordance with the Company's Stock Option Plan.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:Stem Cell Therapeutics Corp.Alan Moore, PhDPresident and CEO403-245-5495 ext.224amoore@stemcellthera.comStem Cell Therapeutics Corp.Angelika Goncalves DaSilvaOperations ManagerPhone: 403-245-5495 ext. 221adasilva@stemcellthera.comwww.stemcellthera.com
SOURCE: Stem Cell Therapeutics Corp.
mailto:amoore@stemcellthera.com mailto:adasilva@stemcellthera.com http://www.stemcellthera.com
Copyright 2010 Marketwire, Inc., All rights reserved.
Source MARKET NEWS
Date 08/27/2010
Time 02:12:57 PM
Company ALDA Pharmaceuticals Corp.
Title Private Placement-Non-Brokered
CDNX Symbol: APH
Press Release
Private Placement-Non-Brokered --->@NEWS RELEASE
ALDA PHARAMACEUTICALS CORP. ("APH")
- Private Placement-Non-Brokered
TSX Venture Tier 2 Company
TSX Venture Exchange has accepted for filing documentation with respect to
a Non-Brokered Private Placement announced July 27, 2010:
Number of Shares: 3,275,000 shares
Purchase Price: $0.10 per share
Warrants: 3,275,000 share purchase warrants to purchase 3,275,000
shares
Warrant Exercise Price: $0.20 for a two year period
Number of Placees: 25 placees
Insider / Pro Group Participation:
Insider=Y /
Name ProGroup=P / # of Shares
Raymond Martin P 100,000
Allan Fabbro P 200,000
Terrance Owen Y 400,000
Peter Chen Y 150,000
William F. McCoy Y 22,500
Ronald Zoko Y 105,000
Finder's Fee: $1,000 Cash payable to Canaccord Genuity Corp.
$1,250 Cash payable to Northern Securities Inc.
Pursuant to Corporate Finance Policy 4.1, Section 1.11(d), the Company must
issue a news release announcing the closing of the private placement and
setting out the expiry dates of the hold period(s). The Company must also
issue a news release if the private placement does not close promptly.
[Note that in certain circumstances, the Exchange may later extend the
expiry date of the warrants, if they are less than the maximum permitted
term.]
______________________________________
_______________________________________________
Capitalization Report for Alda Pharmaceuticals Corp
Shares Issued: 58731799
Shares Escrow: 0
TSX Venture closing price for Alda Pharmaceutic
Date: 2010/08/26
Closing Price: 0.115
____________________________________________________________
(c)2010 Market News Publishing Inc. All rights reserved.
Toronto:(416)366-8881 Vancouver:(604)689-1101 Fax:(604)689-1106
1023800072TS11023801955-14101620100827
ALDA Pharmaceuticals Proposes Extension of Exercise Period of 6,000,000 Outstanding Share Purchase Warrants
VANCOUVER, BRITISH COLUMBIA, Aug 03, 2010 (MARKETWIRE via COMTEX News Network) --
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCQB: APCSF) ("ALDA" or "the Company") announces that it is seeking an extension of the exercise period of an aggregate of 6,000,000 outstanding share purchase warrants issued as part of the non-brokered private placement of common share units which closed on September 16, 2009. Pursuant to the proposed extension, the applicable exercise period will be extended by one further year, from September 16, 2010 to September 16, 2011. The warrant exercise price of $0.40 per share will remain the same. Insiders of the Company hold 50,000 of the outstanding share purchase warrants subject to the proposed amendment.
The proposed extension is subject to the warrant holders entering into definitive amendment agreements and the acceptance of the TSX Venture Exchange. The amendment provides ALDA with an extended opportunity to receive funding for general corporate purposes from existing warrant holders.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor Relations 604-377-5781 or 604-521-8300 Ext 2 604-521-8322 (FAX) scott_young@aldacorp.com www.aldacorp.com
SOURCE: ALDA Pharmaceuticals Corp.
mailto:scott_young@aldacorp.com http://www.aldacorp.com
Copyright 2010 Marketwire, Inc., All rights reserved.
ALDA Pharmaceuticals to Undertake Revised Private Placement
VANCOUVER, BRITISH COLUMBIA, Jul 27, 2010 (MARKETWIRE via COMTEX News Network) --
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCQB: APCSF)(PINK SHEETS: APCSF) (the "Company") announces that, as a result of prevailing market conditions, the private placement financing originally announced on April 15, 2010 (and subsequently revised as disclosed in the Company's news releases of April 28th and May 28th), will not be proceeding on the terms disclosed. The Company is proceeding with a smaller private placement of $325,000 to be used for general corporate purposes by the sale of 3,250,000 share purchase units on a private placement basis, pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange, at $0.10 per unit. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.20 per common share for a period of two (2) years from the date of the issuance of the purchase warrant with an accelerated exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.40 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly.
Insiders of ALDA will be subscribing for 25% of the offering, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9 which is exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101. Their participation will be on the same terms as arm's length investors, and such insiders' shareholdings in the Company will increase as a result of any such participation. The revised private placement is intended to close within the next week as soon as the requisite approvals of the TSX Venture Exchange are obtained.
The Company also wishes to clarify that a report on the TSX Venture Exchange website on Tuesday, July 20, 2010 that an insider sold 108,500 shares at $0.12 was not correct. The Company has confirmed that the transaction did not involve a current insider of the Company and was incorrectly designated as such on the TSX Venture Exchange website.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The Company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.
Terrance G. Owen, Ph.D., MBA, President & CEO, ALDA Pharmaceuticals Corp.
The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the "Act") and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor Relations 604-377-5781 or 604-521-8300 Ext 2 604-521-8322 (FAX) scott_young@aldacorp.com www.aldacorp.com
SOURCE: ALDA Pharmaceuticals Corp.
mailto:scott_young@aldacorp.com http://www.aldacorp.com
Copyright 2010 Marketwire, Inc., All rights reserved.
Thank you for the message, and I'm glad that you are doing well. Apparently my French is still pretty good. I only had problems with a couple of words; but I got the jist of it.
Sounds interesting JC. I will definitely look into it some more.
I certainly hope that you are right, because I decided not to take the loss; so I did not sell. I have made money on this stock a couple of times already; but this time it would definitely be a sizable loss. Anyway, its summer and the weather is great, so I guess I will enjoy it and check back in later in the year and hope there is something more positive to read. Have a good summer! :)
The news is not good!
CALGARY, ALBERTA--(Marketwire - June 25, 2010) - Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) announces the following updates:
Ongoing Stroke Trial Analysis
On May 25, 2010, the Company announced top-line results for the modified REGENESIS-Phase IIb stroke trial, a placebo controlled, double blinded, 3:1 randomized clinical study that enrolled 96 patients with acute ischemic stroke between August 2009 and January 24, 2010. SCT reported that the top-line analysis for this clinical trial of NTx(R)-265 in acute stroke showed that there was substantial improvement in the primary efficacy endpoint (absolute change in NIHSS) in both placebo treated patients and those receiving NTx(R)-265, with no statistical differences between the groups.
After further analysis of the trial results, management has been unable to determine a definitive explanation for the unexpectedly large placebo effect encountered in the modified REGENESIS-Phase IIb stroke trial. Further analysis has, however, indicated that some of the secondary endpoints that were also measured as part of the trial demonstrate a trend that shows greater efficacy in those patients who received the NTx(R)-265 therapy versus those who were given the placebo. None of these secondary endpoints had sufficient patient populations to demonstrate statistically significant differences; nevertheless the trends are considered by management to be encouraging. Analysis of the trial results is ongoing and all calculations are subject to validation in the final report which is expected to be completed by the end of August.
In light of these positive trends, and the excellent safety profile for NTx(R)-265 as demonstrated by the modified REGENESIS-Phase IIb stroke trial, management of the Company believes that it would be worthwhile to proceed to an end-of-Phase II meeting with the FDA in which they will seek approval to proceed with a Phase III stroke study for NTx(R)-265. Management's objective is to have such meeting in October of this year. There can be no assurance that the FDA will grant approval for a Phase III stroke trial.
Cost Cutting Program
Even if the Company is successful in obtaining FDA approval to conduct a Phase III stroke trial for NTx(R)-265, the Company's ability to continue further stroke studies is uncertain at this time due to its limited capital and the failure to meet the primary efficacy endpoint in the modified REGENESIS-Phase IIb stroke trial. Accordingly, the Board of Directors has decided to implement a cost-cutting program to preserve as much capital as possible while management pursues the end-of-Phase II meeting with the FDA. As part of this program, the employment contracts for each of the senior officers of the Company (CEO, CFO, VP Product, Development and VP, Commercial Planning) have been terminated effective June 30, 2010. Alan Moore, the current CEO, and Barry Herring, the current CFO have agreed to stay on with the Company in their current capacities on a consulting basis for the following six months to assist the Company in its attempt to maximize the value of its intellectual property. The Company has made a similar consulting offer to Alan Davidoff, the current VP, Product Development and expects to have a response next week. Also, as part of the cost cutting program, other staff positions will be eliminated or reduced, certain external research and service contracts will be terminated, and the Company will significantly reduce the size of its office space. The estimated cost of effecting the employee terminations and other cutbacks discussed above is approximately $540,000. Management estimates that after giving effect to the cost cutting program, the Company will have a cash balance of approximately $1.4 million at the end of 2010, with little or no severance, lease or other contractual obligations at such time. The Board believes that taking these steps now will put the Company in the strongest financial position to consider and pursue strategic alternatives for maximizing future shareholder value.
Board of Directors
Bob Rieder resigned as a director of the Company effective June 24, 2010. The remaining Board members have verbally indicated their intention to remain on the Board until at least the end of 2010.
Outlook for Remainder of 2010
During the next six months, management will focus its efforts on pursuing the end-of-Phase II meeting with the FDA for the NTx(R)-265 stroke therapy, as discussed above. This is expected to be a low-cost initiative. At the same time, management and the Board will review alternatives for pursuing the traumatic brain injury ("TBI") and multiple sclerosis ("MS") study opportunities that have been discussed in the past. The focus in this regard will be to determine the best way to finance such studies through to their completion. In addition to the foregoing, management and the Board will also consider other strategic alternatives for the Company. This might involve the engagement of a financial advisor and/or the appointment of a Special Committee of the Board. No such steps have been taken at this time as the current priority is to implement the cost cutting program described above and allow management to begin pursuing the initiatives discussed in this press release. Further updates will be announced as developments warrant.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit http://www.stemcellthera.com.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements, including specifically estimated expenses and future cash balances, involve risk and uncertainties, which may cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Investment Industry Regulatory Organization of Canada - Trading Halt - Stem Cell Therapeutics Corp. - SSS - V
Il y a 5 minutes - ACQUIREMEDIA
VANCOUVER, June 24 /CNW/ - The following issues have been halted by Investment Industry Regulatory Organization of Canada (IIROC):
<<Issuer Name: Stem Cell Therapeutics Corp.TSX-V Ticker Symbol: SSS - VTime of Halt: 9:05 ESTReason for Halt: Company Request Pending News>>
Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent
16 minutes ago - ACQUIREMEDIA
CALGARY, ALBERTA--(Marketwire - June 8, 2010) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") is pleased to announce today that it has been granted U.S. Patent 7,704,737 entitled, "Oligodendrocyte Production from Multipotent Neural Stem Cells". The claims cover the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to issue in this patent family.
Dr. Alan Moore, President and CEO, commented as follows:
"The technology covered by this patent is of potential use as cell transplant therapy for treating demyelinating diseases resulting from oligodendrocyte loss or damage, such as multiple sclerosis and spinal cord injury. This patent expands and adds value to SCT's overall intellectual property portfolio."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT:
Stem Cell Therapeutics Corp.
Alan Moore, PhD
President and CEO
403-245-5495 ext.224
amoore@stemcellthera.com
Stem Cell Therapeutics Corp.
Angelika Goncalves DaSilva
Operations Manager
403-245-5495 ext. 230
adasilva@stemcellthera.com
www.stemcellthera.com
Source: Stem Cell Therapeutics Corp.
Avion Intersects 5.79 g\t Au Over 12.0 Metres at Djambaye II Zone-Zone Open Down Plunge
TORONTO, ONTARIO, Jun 03, 2010 (MARKETWIRE via COMTEX News Network) --
Avion Gold Corporation (TSX VENTURE: AVR)(OTCQX: AVGCF)(PINK SHEETS: AVGCF) ("Avion") is pleased to announce the results from core and reverse circulation drill holes that tested a 900 metre long portion of the Djambaye II zone located on the Kenieba Property (see Avion News Releases dated December 21, 2009 and January 8, 2010). The Kenieba Property lies 6.5 kilometres southwest of the Tabakoto Mine/Mill complex, adjacent to the south and southwestern boundary of Avion's Tabakoto Property (see attached figure 1). The property hosts the Djambaye II deposit (Inferred resources of 324,000 ounces of gold, in 2,574,000 tonnes grading 3.92 grams per tonne gold).
Highlights of this drilling, which tested the near-surface and depth extensions of the deposit comprise the following:
-- 5.79 g/t Au over 12.0 metres in drill hole G-10-07-- 29.80 g/t Au over 2.3 metres in drill hole G-10-08-- 7.77 g/t Au over 4.7 metres in drill hole G-10-17-- 3.89 g/t Au over 11.6 metres in drill hole G-10-18-- 4.89 g/t Au over 8.7 metres in drill hole G-10-23-- 9.47 g/t Au over 3.9 metres in drill hole G-10-57
Results for a 900 metre long portion of the steep east dipping Djambaye II hangingwall (HW) zone are presented in this news release (see figure 2). Within this northern section of the Djambaye II zone, drilling has defined a 400 metre long, shallow-south-plunging zone of higher grade gold mineralization. This higher grade portion of the Djambaye II zone can be traced to 240 metres vertical depth along an open ended 640 metre plunge extent. One of the deepest holes on the zone returned 9.47 g/t Au over 3.9 metres core length; intercepts like this and others support the underground potential of this zone. The higher grade sections of this zone (above a grade times width of 11 gram(i)metres) returned a weighted grade of 5.3 g/t Au (4.92 g/t capped at 30 g/t Au) over an average true width of 6.0 metres. This compares favorably with the Company's Segala Deposit where overall mined gold grades average between 3.5 g/t Au to 4.0 g/t Au.
A second parallel zone of gold mineralization, Djambaye footwall (FW) zone, lies approximately 15 to 20 metres to the west. This zone has been intersected by 37 core and reverse circulation holes along a 540 metre strike length and to 240 metres depth (see figure 3). It appears to be open to depth and to the north. Hole GRC-10-11 returned the best results with an intercept of 10.66 g/t Au over 5.0 metres. The second best intercept of 6.3 g/t Au over 4.3 metres was returned from hole G-10-2, which represents a 160 metre step-out from the previous resource block; additional drilling will be carried out in this area. This zone has an average weighted grade, from all holes on the long section, of 2.47 g/t Au over an average true width of 2.8 metres.
This news release presents results for 24 reverse circulation and 53 diamond drill holes totaling 6,617.5 metres that were completed by Avion in 2010. Once all drill data and sectional interpretations have been completed the Company plans to update the historic resource with a goal to define additional open pittable resources.
John Begeman, Avion's President and CEO, stated, "These results support reasonable potential for the definition of good grade, shallow open pit mineable resources for Avion, which in turn has the potential to provide Avion with greater flexibility as we move to develop underground mines at Tabakoto and Segala. This zone also provides an opportunity to define gold mineralization with adequate grades and widths that could potentially support underground mine development and additional immediate open pit resources."
Avion's procedures for handling core and reverse circulation drill chips have been presented in previous news releases (See for e.g. Avion News Release dated May 13, 2010).
Don Dudek, P.Geo. the Senior Vice President, Exploration of the Company and a qualified person under National Instrument 43-101, has reviewed the scientific and technical information in this press release.
About Avion Gold Corporation
Avion is a Canadian-based gold mining company focused in West Africa that holds 80% of the Tabakoto and Segala gold projects in Mali. Gold production commenced at these projects in 2009 with just over 51,000 ounces produced; 2010 production is estimated at 75,000 to 85,000 ounces. Production sustainability is supported and enhanced by an aggressive 2010 drill program over an approximately 600 km2 exploration package that both surrounds and is near to our existing mine infrastructure. Additionally, a new, 1,670 km2 exploration property in Burkina Faso is expected to return good results from an ongoing drill program. These properties are the subject of a approx.US$ 12 million dollar, 60,000 metre plus, drill-focused exploration program in 2010, which is expected, based on results to date, to add new resources and future opportunities for Avion. Avion continues to progress towards its longer term goal of 200,000 ounces of gold per year and is evaluating an underground mine plan for the Segala and Tabakoto deposits. Avion has a highly skilled management team, with a focus on growth and consolidation within West Africa.
Cautionary Notes
The ability of Avion to increase production to 200,000 ounces of gold per year has not been the subject of a feasibility study and there is no certainty that the proposed expansion will be economically viable.
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the impact of the drilling results on the Company; statements with respect to the development potential and timetable of the Mali projects; the future price of gold; the estimation of mineral resources; conclusions of economic evaluation (including scoping studies); the realization of mineral resource estimates; the timing and amount of estimated future production, development and exploration; costs of future activities; capital and operating expenditures; success of exploration activities; mining or processing issues; currency exchange rates; government regulation of mining operations; and environmental risks. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; the actual results of current exploration activities; ability to successfully integrate the purchased properties; foreign operations risks; other risks inherent in the mining industry and other risks described in the annual information form of the Company which is available under the profile of the Company on SEDAR at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
Djambaye II Zone Intercept Summary(i) (1)
----------------------------------------------------------------------------
Assay g/t Core length True Width Capped Assay
Drill Hole # Zone Au (m) (m) g/t Au
----------------------------------------------------------------------------
G-10-01 FW 0.02 3 2.5 0.02
G-10-01 FW 0.14 1.2 1 0.14
G-10-02 FW 0.27 1.6 1 0.27
G-10-02 FW 0.28 1.25 1 0.28
G-10-03 FW 0.28 1.25 1 0.28
G-10-03 FW 0.44 1.8 1.5 0.44
G-10-08 FW 0.425 8 5 0.425
G-10-08 FW 1.15 2 2 1.15
G-10-08 FW 0.81 3.5 3 0.81
G-10-11 FW 0.47 8.7 7 0.47
G-10-12 FW 1.32 6 5 1.32
G-10-13 FW 0.5 2.2 1.7 0.5
G-10-13 FW 1.91 1.2 1 1.91
G-10-14 FW 1.49 4.2 3.5 1.49
G-10-14 FW 1.81 4 3 1.81
G-10-20 FW 2.62 6.4 5.5 2.62
G-10-20 FW 3.4 7.3 6 3.4
G-10-29 FW 1.21 2.95 2.9 1.21
GRC-10-02 FW 0.24 5.3 4.8 0.24
GRC-10-04 FW 1.83 3 2.8 1.83
GRC-10-04 FW 1.71 3.8 3 1.71
GRC-10-05 FW 2.14 3 3 2.14
GRC-10-06 FW 4.09 3.35 3 4.09
GRC-10-07 FW 2.1 6.1 6 2.1
KN-08(ii) FW 2.7 3.3 3 2.7
KN-08(ii) FW 2.41 5 4.5 2.41
KN-08(ii) FW 15.8 1.8 1.5 15.8
KN-11(ii) FW 2.36 3.3 2.8 2.36
KN-12(ii) FW 0.86 3.95 3 0.86
KN-12(ii) FW 1.1 4 3 1.1
KN-14(ii) FW 2.64 3 2.5 2.64
KN-14(ii) FW 4.38 2 2 4.38
KN-14(ii) FW UG UG
KN-15(ii) FW 1.55 2.45 2 1.55
KN-15(ii) FW 2.43 1.85 1.5 2.43
KN-16(ii) FW 5.43 3 1.5 5.43
KN-16(ii) FW 6.3 4.3 4 6.3
KN-43(ii) FW 1.99 3 2 1.99
KN-43(ii) FW 2.24 2 2 2.24
KN-43(ii) FW 1.22 4.25 4 1.22
KN-44(ii) FW 4.85 3.78 3.2 4.85
KN-44(ii) FW 10.66 5 5 8.56
G-10-07 HW 1.69 5.3 4.5 1.69
G-10-09 HW 1.43 0.4 0.3 1.43
G-10-09 HW 0.26 3.6 3 0.26
G-10-10 HW 0.93 2.4 2 0.93
G-10-10 HW 0.84 3 2.5 0.84
G-10-14 HW 0.803 9.85 8.5 0.803
G-10-15 HW 1.49 3.2 2.5 1.49
G-10-15 HW 0.96 4.7 4 0.96
G-10-16 HW 1.56 4.19 3.5 1.56
G-10-17 HW 3.06 2.1 1.75 3.06
G-10-18 HW 1.86 4.1 4 1.86
G-10-19 HW 2.9 4.05 3.5 2.9
G-10-21 HW 1.55 1 0.75 1.55
G-10-21 HW 0.44 3.7 3 0.44
G-10-22 HW 3.04 8 5 3.04
G-10-23 HW 6.96 3 2.75 6.96
G-10-24 HW 1.98 10.5 9 1.98
G-10-25 HW 2.53 10.4 8 2.53
G-10-26 HW 10.69 3.3 3 10.69
G-10-27 HW 2.62 15.6 8 2.62
G-10-28 HW 12.02 4.1 3.5 12.02
G-10-30 HW 3.56 10 8 3.56
G-10-31 HW 3.61 0.55 0.5 3.61
G-10-31 HW 0.4 6.5 5 0.4
G-10-33 HW 1.39 6.6 5.5 1.39
G-10-34 HW 2.54 5 4 2.54
G-10-35 HW 3.46 3.3 3 3.46
G-10-36 HW 0.97 12.1 12 0.97
G-10-37 HW 6.11 2.8 2.5 6.11
G-10-38 HW 2.75 7.7 7 2.75
G-10-39 HW 3.82 11 9 3.82
G-10-40 HW 7.7 4.7 4.5 7.7
G-10-41 HW 29.8 2.3 2 23.1
G-10-42 HW 1.51 1.7 1.5 1.51
G-10-43 HW 3.34 1.72 1.5 3.34
G-10-43 HW 1.29 4 4 1.29
G-10-45 HW 3.12 4 3 3.12
G-10-46 HW 2.46 6 4.5 2.46
G-10-47 HW 2.74 10.05 6.5 2.74
G-10-48 HW 2.53 10.4 8 2.53
G-10-49 HW 9.47 3.9 3 9.47
G-10-50 HW 9.87 4.4 4 9.87
G-10-51 HW 5.79 12 11 5.79
G-10-52 HW 0.47 1.48 1 0.47
G-10-52 HW 0.64 1.5 1.2 0.64
G-10-54 HW 27.69 2.9 2.7 15.7
G-10-55 HW 3.98 26 18 3.7
G-10-57 HW 21.03 7.6 6.5 21.03
G-10-58 HW 8.34 7 3 8.34
G-10-58 HW 10.69 2.96 2.5 10.69
G-10-59 HW 4.07 2.2 2 4.07
G-10-59 HW 1.44 7.2 6 1.44
G-10-86 HW 1.88 5.8 5 1.88
GRC-10-09 HW 0.64 2 1.5 0.64
GRC-10-11 HW 0.87 2 2 0.87
GRC-10-13 HW 0.75 3.1 2.5 0.75
GRC-10-14 HW 2.17 1.2 1 2.17
GRC-10-16 HW 0.92 5.1 4 0.92
GRC-10-18 HW 2.47 2.9 2 2.47
GRC-10-18 HW 1.66 3.4 3 1.66
GRC-10-19 HW 2.15 3.5 3 2.15
GRC-10-21 HW 2.89 3.1 2.5 2.89
GRC-10-22 HW 1.13 8.76 8 1.13
GRC-10-27 HW 2.84 4.5 4 2.84
GRC-10-28 HW 3.6 7 4 3.6
GRC-10-30 HW 4.5 4.1 3.5 4.5
GRC-10-31 HW 8.56 2.3 2 8.56
GRC-10-33 HW 2.68 10 7.5 2.68
GRC-10-34 HW 5.4 6.67 5 5.4
GRC-10-35 HW 3.89 11.6 9 3.89
GRC-10-36 HW 4.89 8.7 8 4.89
GRC-10-41 HW 1.06 13.5 10 1.06
GRC-10-46 HW 0.81 10.1 8 0.81
KN-03(ii) HW 2.32 7.4 5 2.32
KN-05(ii) HW 3.34 6.25 4 3.34
KN-06(ii) HW 1.93 3.2 3 1.93
KN-07(ii) HW 1.57 3.8 3.8 1.57
KN-07(ii) HW 2.19 3.7 3 2.19
KN-08(ii) HW 2.35 5.8 5 2.35
KN-09(ii) HW 0.73 4.01 3.5 0.73
KN-10(ii) HW 1.54 2.1 2 1.54
KN-10(ii) HW 0.82 6.5 5 0.82
KN-17(ii) HW 2.26 2.3 1.7 2.26
KN-17(ii) HW 0.88 4.75 4.5 0.88
KN-18(ii) HW 1.42 3.8 3.2 1.42
KN-18(ii) HW 1.6 3.7 3 1.6
KN-19(ii) HW 1.97 8.25 2.5 1.97
KN-21(ii) HW 2.53 2.6 2.4 2.53
KN-21(ii) HW 2.03 3.8 3.5 2.03
KN-22(ii) HW 2.5 6.55 5.5 2.5
KN-23(ii) HW 2.8 8.09 7 2.8
KN-24(ii) HW 14.08 2.8 2.5 12.4
KN-29(ii) HW 7.38 3.4 3 7.38
KN-31(ii) HW 0.46 1.45 1.2 0.46
KN-35(ii) HW 2.1 13.2 11 2.1
KN-36(ii) HW 12.7 6 5 6.81
KN-45(ii) HW 0.47 7.8 7 0.47
KN-46(ii) HW 1.98 4.9 4 1.98
KN-47(ii) HW 1.6 12.9 9 1.6
KN-48(ii) HW 3.01 8.5 8 3.01
KN-49(ii) HW 18.97 5 3.5 14.07
KN-50(ii) HW 7.53 20 10 7.3
----------------------------------------------------------------------------
(i) Assay capped at 30 g/t Au
(ii) Historic Great Quest Metals Ltd.
(1) All GRC prefix holes were reported in a previous Avion
News release (March 22, 2010)
UG - Artisanal underground workings
To view the Tabakoto Project figure, please visit the following link:
http://media3.marketwire.com/docs/TabakotoProject.pdf.
To view the Djambaye II HW Zone figure, please visit the following link:
http://media3.marketwire.com/docs/Djambaye-II-HW-Zone.pdf.
To view the Djambaye II FW Zone figure, please visit the following link:
http://media3.marketwire.com/docs/Djambaye-II-FW-Zone.pdf.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Contacts: Avion Gold Corporation Don Dudek Senior Vice President Exploration (416) 861-2261 don@aviongoldcorp.com
SOURCE: Avion Gold Corporation
mailto:don@aviongoldcorp.com
Copyright 2010 Marketwire, Inc., All rights reserved
AVR up 12% yesterday!
Barrick Gold Corporation and Avion Gold Corporation Under Continued Evaluation
May 11, 2010 (ACCESSWIRE via COMTEX News Network) --
Barrick Gold Corporation and Avion Gold Corporation Under Continued Evaluation
Equedia.com and Equedia Weekly provides research on the top Canadian companies with a focus on mining and resource stocks. Equedia is continuing research and evaluation on the prospects of Barrick Gold Corporation (TSX: ABX) and Avion Gold Corporation (TSX VENTURE: AVR). To be further notified of our updates on these companies and special report editions through our Equedia Weekly Newsletter, please obtain your free subscription here:
http://equedia.com/newsletter
Companies previously featured in our special report editions have hit new 52 - week highs since the initiation of our coverage and many companies under evaluation have made strong gains since being placed under evaluation. To receive these reports, please make sure to subscribe for your complimentary subscription to Equedia Weekly here:
http://www.equedia.com/newsletter
Here is a brief excerpt from one of our past newsletters with our story on, "The Secret Battle":
"Every junior miner strives to become a producer, or to be bought out. Both of these paths take a lot of financing and dilution before the end goal. It takes much more than just some drill holes to succeed. The hard truth is, mining exploration and development is a negative cash flow business.
Juniors need to continually raise money for the many processes involved in bringing a mine to life. They need to drill enough holes to gain enough interest from the majors for a buyout. This ultimately leads to further dilution.
Many will fail.
But what if there is a junior that is cash flow positive before production? What if there was a company with revenues nearing $16 million in their previous year? What if there was a company with an 80% interest in a property with over $12 million in expenditures in the last two years, a 43-101 resource, a historical "reserve" sitting between two of the world's largest silver mines, and expecting production in Q1 of 2011? What if they were fully permitted and fully funded to begin production?
Is there such a company? There is. And it's..."
To continue reading and receive your next free edition of Equedia Weekly, please subscribe by going to http://equedia.com/newsletter/ and visit http://equedia.com/blog/view.php/Special-Report-Edition-The-Secret-Battle for the latest edition.
You should also visit www.equedia.com to gain access to insider information, analyst ratings, videos, corporate coverage, financials, and in-depth stock charts for the above mentioned companies. Shareholders are also asked to assist our staff by providing us more details on your knowledge of the above-mentioned companies as we put them under evaluation. By registering through www.equedia.com, you can upload your findings and attach them to the respective companies under their corporate landing page.
Register through the following link to gain access:
http://equedia.com/login.php
The Equedia Weekly investment video newsletter features stock picks, videos and investment strategies from North America's leading investment personalities and gives you free access to a minimum of 6 special reports per year featuring the best Canadian mining and resource stocks.
Our Free Newsletters include: Mining and Resource Stocks Research, Stock Picks, Trading Strategies, Video Tutorials, Analyst Videos, Options Trading, Investment Tips, and Much More!
Equedia Weekly updates its subscribers on the top performing and undervalued Canadian mining stocks including the stocks mentioned in this release. Sign up today and receive your free subscription to our interactive multimedia newsletter here:
http://www.equedia.com/newsletter
About Equedia
Equedia is N. America's leading interactive investment newsletter and investor network with many advanced social networking features. The Equedia platform caters to companies and investment media who want to communicate with stakeholders via video content, as well as through blogs, shared calendars, and other features.
The Equedia Weekly Investment Newsletter is aimed at mining and resource stocks with a strong focus on the top Canadian stocks in the industry. It features investment ideas and content from our top performing and respected partners including N. America's leading analysts and investment personalities.
We have not been compensated by any of the above-mentioned companies and do not own a position at the time of this writing. However, we may buy and sell shares on the open market without notice to our readers.
All material herein was prepared by Equedia Network Corporation ("Equedia") based upon information believed to be reliable. The information is not guaranteed by Equedia to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Equedia is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker or investment professional before purchasing or selling any securities mentioned herein.
Contact:
Equedia Network Corporation
www.equedia.com
Telephone: 1-888-EQUEDIA (378-3342)
Email: info@equedia.com
Copyright 2010 ACCESSWIRE
You are right on surf. It's just like on SH, when the bashers appear, you know good things are usually on the horizon.
Rage Against The Machine :)
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCBB: APCSF) (the "Company") announces that, in response to investor interest, the private placement financing announced on April 15, 2010 has been increased to 3,080,000 units of the Company (the "Units") at a price of $0.20 per Unit for proceeds to the Company of $616,000. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.30 per common share for a period of two (2) years from the date of the issuance of the purchase warrant with an accelerated exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.60 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days.
As announced in the April 15th news release, the offering is being made on a private placement basis pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly. Net proceeds from the offering will be used for general corporate purposes.
Insiders of ALDA will be subscribing for 25% of the offering, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9 which is exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101. Their participation will be on the same terms as arm's length investors, and such insiders' shareholdings in the Company will increase as a result of any such participation. The private placement may close before 21 days following the filing of the material change report regarding this announcement if management determines it to be necessary or desirable for sound business reasons.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The Company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company is the Official Supplier of the Vancouver 2010 Olympic Winter Games, Vancouver 2010 Paralympic Winter Games, the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
www.aldacorp.com
The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the "Act") and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor Relations 604-377-5781 or 604-521-8300 Ext 2 scott_young@aldacorp.com www.aldacorp.com
SOURCE: ALDA Pharmaceuticals Corp.
mailto:scott_young@aldacorp.com http://www.aldacorp.com
Copyright 2010 Marketwire, Inc., All rights reserved.
ALDA Pharmaceuticals Appoints Medical Director
VANCOUVER, BRITISH COLUMBIA, Apr 16, 2010 (MARKETWIRE via COMTEX News Network) --
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCBB: APCSF) (the "Company" or "ALDA") announces that Dr. Brian Conway has been appointed as Medical Director. Dr Terrance Owen, President & CEO, states, "Since 2003, Dr. Conway has provided excellent advice to the Company as a Scientific Advisor. However, now that we are preparing to implement a comprehensive program of pre-clinical and clinical trials of T36(R) preparations, we need Dr. Conway's expertise to assist with the design and implementation of the protocols, review the findings and interact with the regulatory agencies. His participation will greatly facilitate the registration of ALDA's therapeutic products in the US, the EU and Canada."
About Dr. Conway
Brian Conway, M.D. is a full-time Professor at the University of British Columbia, Department of Anesthesiology, Pharmacology and Therapeutics. He is Coordinator of the Downtown Infectious Diseases Clinic in Vancouver, Infectious Diseases Consultant with the Vancouver Coastal Health Authority and Infectious Diseases Consultant at the Yale Medical Clinic. Dr. Conway is Co-chair of the Ministerial Council for the federal initiative on HIV and AIDS, working with and reporting directly to the Health Minister. He is the president of the Societe Sante en francais, a federal group charged with the development of health care services for Canadian francophones living outside Quebec. He is the past president of the Canadian Association for HIV Research and co-chair of its upcoming 19th Annual Conference in May 2010 in Saskatoon.
Dr. Conway is deeply involved in a range of HIV-related research and clinical practice efforts. His programs have received a number of awards for their innovation and success, including the Health Employers Association of British Columbia Award of Excellence in 2008. He was the Francophone of The Year in British Columbia in 2007 for his work in the development of culturally and linguistically optimized systems of care for minority populations. He is a peer reviewer for 13 medical journals and the primary or senior author of more than 120 peer-reviewed publications. He has been an invited speaker at many international HIV conferences and meetings dealing with HIV.
Dr. Conway received his medical education at McGill University, from which he graduated in 1982 before completing his internship and residency at Queen Elizabeth Hospital and Royal Victoria Hospital, respectively. He completed a specialty fellowship in infectious diseases at the University of Manitoba in 1988, and a post-doctoral fellowship in HIV/AIDS at Harvard University in 1990. His first staff appointment was as an Assistant Professor at the University of Ottawa in 1990. He moved to the University of British Columbia in 1994, where he is now a tenured Full Professor.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was appointed as the Official Supplier of the Vancouver 2010 Olympic Winter Games, Vancouver 2010 Paralympic Winter Games, the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
www.aldacorp.com
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor Relations 604-377-5781 or 604-521-8300 Ext 2 604-521-8322 (FAX) scott_young@aldacorp.com www.aldacorp.com
SOURCE: ALDA Pharmaceuticals Corp.
mailto:scott_young@aldacorp.com http://www.aldacorp.com
Copyright 2010 Marketwire, Inc., All rights reserved.
After trading 14 1/2 million shares, you had to know this was going to happen when all of the day traders pulled out. I'm quite sure even long term holders/believers did some trading over the past couple of days. Personally, I bought some; but I did not sell any. I was lucky enough to be in front of my computer when the price was still fairly low. All in all, I'd say we held up pretty well all concidered. Let's see what happens today; and especially over the coming weeks.
Yes, congratulations to all! It was certainly hard at times to be patient; but it looks like we are all going to make some really good money on Alda after all. Hey stick, where are you? It’s time for a little celebrating, and soon some major celebrating I suspect.
Yes I like that reply from the AG board as well and this is Realtime's original post/theory which I also like! :)
Have given this some thought today and have come up with an interesting hypothesis. Neither TO or Scott seemed overly worried about the sp or Step one . That to me seemed odd, The fact that they could advertise without any kind of repercussions. Alda is the official supplier that is a given and therefore if my hypothesis is correct aph must have allowed the advertising. If I follow this bit of conjecture there would have to be a reason. Money, is it possible that step one paid aph for the privledge, or is it possible that we may have a buyout or partnership in the works. Shapero is gone, and according to one other poster, cannot remember if it was this board or SH so are the 2 people from marketing. I have not verified this but it fits with my theory so allow me to go with it for now. No shapero so theraputic applications on hold, no marketing. And insiders who are not selling but buying.
So what does aph have that Step One might want. Patents lots of them in various countries. Aph has a market cap of 10 million dollars even if they got a US contract to supply a major chain could they, they could barely keep up with orders here in our small market. But perhaps Step one can. If a partnership or buyout is underway with the patents as the carrot aph would not need shapero or a marketing dep. It kind of fits and I do agree it is a giant leap but plausable.
Well that is part of my theory would really appreciate any opinions for or against. Did not buy any today but am taking a hard look and will watch the trading on thur and fri.
Realtime
This was on the AG Board:
TSX Venture 50 Spotlight
posted on Mar 23, 10 03:22PM
http://www.tmxmoney.com/en/news/interviews/Mar23-2010_APH.htmlTSX Venture 50 Spotlight: ALDA Pharmaceuticals Corp.
In the Technology and Life Sciences sector, ALDA Pharmaceuticals Corp. (TSX-V:APH) is awarded the third spot on the TSX Venture 50. Initially formed as the capital pool company Duft Biotech Capital in May 2000, the firm took over ALDA Pharmaceuticals, completed their qualifying transaction, and began listing as a two-tier company in November 2003.
ALDA has a patented infection control technology currently used in the dental, beauty and first responder industries, with products available in your local drugstore. Their existing line of infection control products, including hand sanitizers and disinfectant cleaners, led to their title as an official supplier to the 2010 Vancouver Winter Olympics.
The company's sales jumped following the Olympic contract. While previous quarters have seen sales around the $50,000-$80,000 mark, last quarter sales reached approximately $1 million, based largely on hand sanitizer use, putting ALDA on the map.
ALDA's market capitalization sits around $10 million, with a share price of approximately $0.17. The company has almost 59 million shares outstanding and sees trading volumes of 100,000 per day.
President, chief executive officer and co-founder Terrance Owen discussed ALDA's achievement with the TSX Venture Exchange.
TSX-V: What does winning the Top 50 award mean to you and your company?
TO: It came as quite a surprise, a total shock, and I'm extremely gratified and pleased. I got a call on a Wednesday afternoon from the TSX Venture Exchange and usually you get calls from the TSX Venture when there's a problem. But he said you've been selected to the Top 50 and I thought that's great! We're certainly promoting it as another form of recognition for the company. It's not just us saying we're great and blowing our own horn, somebody else thinks we're great too.
Out of the 2500 companies on the TSX-V, if you're one of the Top 50 then you must be doing something right. That kind of exposure in the Toronto investment community is going to be very beneficial to us, I will certainly promote it as much as I can.
TSX-V: Can you describe ALDA's product line and where they can be found?
TO: What attracted me to the company was that our patented T36® technology also has therapeutic applications. We've found that its very effective on all topical infections including athletes foot, toe nail infections, insect bites, cuts, scrapes, bruises, it's good for first aid, it's even an effective treatment for psoriasis when combined with something like a steroid for example, so we've got a very comprehensive therapeutic registration program in progress. We're not just a hand sanitizer company, we're pursuing a large market in the therapeutic market as well.
You would see T36® antiseptic hand sanitizer at T&T supermarket, Pharmasave, sometimes in Shoppers Drug Mart, London Drugs on the west coast, and soon in Home Hardware and Rona, so there are a bunch of retail outlets where the product is available.
TSX-V: What was your role in the 2010 Vancouver Winter Olympics?
TO: The official designation is the official suppler for the 2010 Vancouver winter games for antiseptic hand sanitizer disinfectant and disinfectant cleaning products. It almost sounds like we're a janitorial service but really we're more focused on the therapeutic side, it just happens to be that right now the focus is on the janitorial, hand sanitation side. The Olympics gave us huge exposure, we just went from zero to hero overnight. Nobody had heard of us before, and it's really brought us huge benefits
TSX-V: What does ALDA do to stand out amongst other companies in your sector?
TO: I would say the fact that we have products on the market that you can touch and feel, and look at and buy, differentiates us from the crowd. The Olympic sponsorship, having products on the market and having a broad range of therapeutic applications makes us really unique. And when we say we're going to do something, we actually accomplish it. I can't always predict how long it's going to take, but I know exactly how to get there.
TSX-V: What are ALDA's future plans and goals, and how do you plan to achieve them?
TO: During the last few months we went out there and grabbed as much market share as we possibly could, now we're going to fight to keep it. One of our main competitors, and I don't mind mentioning them by name because they have a very good product and they're very well marketed, Purell, is one of our key competitors. We will never displace them but we want to grab as much market share and hang on to it as we can. We're in the process of seeking registrations for our products in the United States and in the European Union, so we can have international sales which is the medium-term plan. The long term plan is to pursue the clinical trials of the therapeutic applications.
Yes, and this is another one of my posts on the AG board for those that do not follow it for whatever reason.
"I decided that Scott probably receives a lot of unpleasant email inquiries of late; so all I did was ask a politely constructed question and he answered it.
I have made money in the past with Alda; so I can't complain too much. Although I do have some long term shares that are under water at the present time, I am considering doubling down. I just haven't decided one way or another yet.
I have asked Scott another question, and if/when he answers it, I will probably decide then.
Have a Good Day"
All of the various sites have their pros and cons. The main thing is that you do not take any of them too seriously. There are personal agendas on any you come across, even this one. :)
Woodstock
That is what I posted on the AG board. He retired in the middle of February.
I was the one who originally posted the info about Dr Shapiro on Ag. I posed the question to Scott and he aswered me very promptly. I thought that I had posted it here, but I guess not.
My question was "Just wondering if a share holders update is being planned any time in the near future?"
My answer was "No specific time frame on a shareholder update is planned however it could be appropriate time for an Olympic update after the Paralympics is completed."
Scott
Should have invested in companies that manufacture snow removal equipment and generators this year. I know what these east coast people are going through. I got stuck in one of the earlier storms south of Pittsburg on my way to Florida. Glad I missed this one on the way home.
Rage Against The Machine
Good for you on scoring those tickets. Was a little dissapointed in Canada's goal tending and experienced defencemen performances against the USA; and yes I know Ryan Miller stood on his head as usual, but still.
Good to know the T36 info. Thanks for that.
Speaking of another possible pandemic. Apparently a third wave starting.
http://www.recombinomics.com/News/02051004/H1N1_Reg4_W3.html
Rage Against The Machine
As far as I'm concerned, it's the wrong time of the year to be concerned about any stocks price. People are selling anything and everything right now. Unless it's a blue chip stock, people are dumping them for now. On the other hand others consider this time of year to be an opportunity to get cheap shares in stocks that they think will rebound in the New Year. I personally think that this is one of them. Time will tell. Until then, Merry Christmas and Happy New Year to all and may all of your decisions be the right ones. Now it's time to have some wine and go for a Sauna.
Nice to hear from you. It’s been pretty quiet around here lately. Last insider trades are as shown below; so not too concerned personally. Anyway, not too much to talk about concerning ALDA at the moment; so I don’t expect the board to get too exciting any time soon. A lot of tax loss selling going on everywhere I’m sure. Happens every year. I may have to do the same with some of my stocks, as I’ve made way too much money so far this year LOL!
Better times ahead in most areas in the new year in my opinion, especially gold, which APH is, professed to be(gold being an adjective in there case.) Only time tells the tale.
Rage Against The Machine
ALDA Pharmaceuticals Corp. (APH) As of December 6th, 2009
Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction # or value acquired or disposed of Unit Price
Nov 12/09 Nov 03/09 Chen, Peter Direct Ownership Common Shares 10 - Disposition in the public market -20,000 $0.670
Nov 12/09 Nov 03/09 Chen, Peter Direct Ownership Common Shares 10 - Disposition in the public market -11,250 $0.660
Nov 10/09 Nov 04/09 Owen, Terrance G. Direct Ownership Common Shares 10 - Disposition in the public market -15,000 $0.700
Nov 10/09 Nov 03/09 Owen, Terrance G. Direct Ownership Common Shares 10 - Disposition in the public market -10,500 $0.720
Nov 10/09 Nov 02/09 Owen, Terrance G. Direct Ownership Common Shares 10 - Disposition in the public market -10,000 $0.650
Nov 10/09 Oct 30/09 Owen, Terrance G. Direct Ownership Common Shares 10 - Disposition in the public market -10,000 $0.600
Nov 09/09 Oct 30/09 Owen, Terrance G. Direct Ownership Common Shares 10 - Disposition in the public market -10,000 $0.560
Nov 05/09 Oct 29/09 Owen, Terrance G. Direct Ownership Common Shares 10 - Disposition in the public market -4,000 $0.520
Nov 05/09 Oct 29/09 Owen, Terrance G. Direct Ownership Common Shares 10 - Disposition in the public market -10,000 $0.520
Nov 04/09 Oct 27/09 Owen, Terrance G. Direct Ownership Common Shares 10 - Disposition in the public market -8,000 $0.520
This site must break a daily record for the number of posts submitted. I’d hate see what would happen if we actually got some serious news.
Rage Against The Machine
All of the news of late is mickey mouse at best and if this latest game was going to be taken to the next level by Wal-Mart, it would be because it was flying off the shelves; which it isn’t. All of the rest of the games would follow on its coat tails to the promised land. They need a game where gods special angels come down from heaven and help these poor saps defeat the evil beings from hell and also help convert people like me. Apparently it needs to be a little quicker, better graphically and also have a better sense of purpose and direction. I’m no gamer; it’s just what I’ve read. Hopefully they are starting to pay attention to some of the better gaming sites and what is being said and suggested.
Rage Against The Machine
Read my post again, my friend. I didn’t say anything about jumping ship. I don’t have a problem putting down a stock that I own if warranted. So far, I just think I may have made a mistake with this one. I’m not a day trader. I haven’t sold a stock for a loss yet; but I do have a few in my duds folder. I never bet more than I can afford to lose; and every now and again one of my duds resurrects itself from the grave. Only time tells the tale.
Rage Against The Machine
Just go hear and scroll down to insider transactions. Lots of other pretty good info as well.
http://finance.yahoo.com/q?s=MSBT.OB
Rage Against The Machine
ALDA Enters into Agreement with Shoppers Drug Mart
VANCOUVER, BRITISH COLUMBIA, Nov 26, 2009 (MARKETWIRE via COMTEX News Network) --
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCBB: APCSF) ("the Company" or "ALDA") announces that it has entered into an agreement with Shoppers Drug Mart Corporation ("Shoppers") that will make the Company's T36(R) Antiseptic Hand Sanitizer available in over 1,170 Shoppers Drug Mart and Pharmaprix stores across Canada. Dr. Terrance Owen, President & CEO, states: "This agreement provides ALDA with widespread national distribution of our products to consumers for the first time. With the rise in H1N1, this development is very timely as it will allow consumers to purchase our effective, competitively priced and Canadian-made T36(R) Antiseptic Hand Sanitizer throughout Canada."
About ALDA Pharmaceuticals Corp. (www.aldacorp.com)
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCBB under the symbol APCSF.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Contacts:ALDA Pharmaceuticals Corp. - Sales ManagementDiane MannAccount Executive604-521-8300, Extension 4diane_mann@aldacorp.comALDA Pharmaceuticals Corp. - Sales ManagementAdriana CikojevicAccount Manager604-521-8300, Extension 6adriana_cikojevic@aldacorp.comALDA Pharmaceuticals Corp. - Sales ManagementTracy HaubrichAccount Manager604-521-8300, Extension 7tracy_haubrich@aldacorp.comShoppers Drug MartRetail Saleswww.shoppersdrugmart.caAcklands-Grainger Inc.Commercial Saleswww.acklandsgrainger.comALDA Pharmaceuticals Corp.Scott YoungInvestor Relations604-377-5781 or 604-521-8300 Ext 8scott_young@aldacorp.comwww.aldacorp.com
SOURCE: ALDA Pharmaceuticals Corp.
mailto:diane_mann@aldacorp.com mailto:adriana_cikojevic@aldacorp.com mailto:tracy_haubrich@aldacorp.com http://www.shoppersdrugmart.ca http://www.acklandsgrainger.com mailto:scott_young@aldacorp.com http://www.aldacorp.com
Copyright 2009 Marketwire, Inc., All rights reserved.
Rage Against The Machine